Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 1.00 |
| ▸ | CA2 | P00918 | 4/20 | 1.00 |
| ▸ | CA12 | O43570 | 2/20 | 1.00 |
| ▸ | CA9 | Q16790 | 2/20 | 1.00 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.54 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.54 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | KLK1 | P06870 | 3/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20919996 | 0.88 | CA1 (0.79) | CA1CA2CA12CA9ORAI1 | |
| Benzoxaborole SCHEMBL461112 | 0.78 | CA1 (1.00) | CA1CA2CA12CA9ORAI1 | |
| Benzoxaborole SCHEMBL595394 | 0.78 | CA1 (1.00) | CA1CA2CA12CA9ORAI1 | |
| Benzoxaborole SCHEMBL19638740 | 0.77 | CA1 (0.96) | CA1CA2CA12CA9PDE4A | |
| Benzoxaborole SCHEMBL27852566 | 0.77 | CA1 (0.96) | CA1CA2CA12CA9PDE4A | |
| SCHEMBL31604280 | 0.75 | CA1 (0.59) | CA1CA2CA12CA9PDE4A | |
| SCHEMBL5583179 | 0.75 | CA1 (0.71) | CA1CA2CA12CA9PDE4A | |
| SCHEMBL20788610 | 0.75 | CA1 (0.59) | CA1CA2CA12CA9PDE3A | |
| SCHEMBL500220 | 0.75 | CA1 (0.71) | CA1CA2CA12CA9PDE4A | |
| SCHEMBL1135342 | 0.73 | PDE4A (0.61) | CA1CA2CA12CA9PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4539855-A1 | BORON CONTAINING PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | Borah, Inc. (US) | 2025-04-23 | — | — | EP | claimed |
| US-20240132525-A1 | BORON CONTAINING PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2024-04-25 | — | — | US | claimed |
| WO-2023244775-A1 | BORON CONTAINING PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | Boehringer Ingelheim Animal Health USA Inc. (US) | 2023-12-21 | — | — | WO | claimed |
| US-11827657-B2 | Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof | Boehringer Ingelheim Animal Health USA Inc. (US) | 2023-11-28 | — | — | US | claimed |
| EP-4263559-A1 | BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | Boehringer Ingelheim Animal Health USA Inc. (US) | 2023-10-25 | — | — | EP | claimed |
| WO-2022133420-A1 | BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-06-23 | — | — | WO | claimed |
| EP-4539855-A1 | BORON CONTAINING PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | Borah, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20240400637-A1 | COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS | PROTOMER TECHNOLOGIES INC. | 2024-12-05 | — | — | US | disclosed |
| WO-2023244775-A1 | BORON CONTAINING PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | Boehringer Ingelheim Animal Health USA Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-11827657-B2 | Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof | Boehringer Ingelheim Animal Health USA Inc. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827657-B2 | Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof | Boehringer Ingelheim Animal Health USA Inc. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11807726-B2 | Method of crosslinking glycosaminoglycans | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-11-07 | — | — | US | disclosed |
| US-11807726-B2 | Method of crosslinking glycosaminoglycans | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-11-07 | — | — | US | disclosed |
| US-20110224171-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. | 2011-09-15 | — | — | US | disclosed |
| EP-2073816-B1 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-7947663-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947663-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2008063300-A2 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827657-B2 | Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof | JAK3, JAK1, JAK2 | CA1 2675/4885CA2 1365/4885CA12 2075/4885 |
| US-20110224171-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | CA1 908/4885CA2 1331/4885CA12 1801/4885 |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | CA1 908/4885CA2 1331/4885CA12 1801/4885 |
| US-20240132525-A1 | BORON CONTAINING PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | JAK2, JAK1, JAK3 | CA1 3872/4885CA2 2180/4885CA12 3153/4885 |
| US-20240400637-A1 | COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS | GPR119, INSR, IAPP | CA1 2619/4885CA2 3495/4885CA12 3952/4885 |
| US-11807726-B2 | Method of crosslinking glycosaminoglycans | CD44, HPSE, CSGALNACT1 | CA1 1113/4885CA2 1440/4885CA12 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.